Novavax
Update in progressNVAX (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Novavax is a biotechnology company that discovers, develops, and commercializes vaccines to prevent serious infectious diseases worldwide. Its products include Nuvaxovid, a COVID-19 vaccine, and the R21 Matrix-M malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer, Takeda, and Serum Life Sciences to develop, manufacture, and commercialize its COVID-19 vaccine. Founded in 1987, it is headquartered in Gaithersburg, Maryland.
Company score
- Sentiment
- 0.42
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.02
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.44
- Governance
- -0.16
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.10
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.26
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. John Charles Jacobs M.B.A.
- Founded1987
- Employees749
- Websitewww.novavax.com
Identifiers
- ISINUS6700024010
- FIGIBBG000NVSBL7
- LEI529900J4GJHPEPQ23205
- CUSIP670002104
- CIK0001000694